undamentalytics Newsletter
Sign in

Akebia Therapeutics, Inc. income statement

In fiscal 2025, Akebia Therapeutics, Inc. reported revenue of $236m, up 47.5% on the year before, operating income of $23.5m (a 9.9% margin) and net income of −$5.3m, or −$0.02 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue002181208335295212292195160236219
Cost of revenue————81452961518674633945
Gross profit————200190−26120712097197174
Research and development234311623129132321814813063386270
Selling, general and administrative——222787149154174139100107107114
General and administrative1518———————————
Operating income−38−62−136−77−178−286−378−265−81−46−5023−15
Net interest income01———————————
Income before tax——−136−74−172−286−385−282−94−52−69−4−28
Income tax————−28−70000022
Net income−37−61−136−74−144−280−385−282−94−52−69−5−30
Diluted EPS−$4.02−$1.15−$1.80−$0.84−$1.24−$2.36−$2.78−$1.70−$0.52−$0.28−$0.33−$0.02−$0.11
Diluted shares (average)31m53m75m87m116m118m138m166m183m187m211m257m263m
EBITDA−38−61−136−76−177−284−376−263−79−45−4925−14

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AKBA vs PBYIAKBA vs IDYAAKBA vs ANABAKBA vs VALN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Akebia Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Akebia Therapeutics, Inc.